Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy
- PMID: 40320487
- DOI: 10.1007/s12032-025-02752-y
Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy
Abstract
Cervical cancer (CC) remains a significant global health burden, particularly in low- and middle-income countries, where access to effective screening and treatment is limited. Despite advancements in conventional therapies, such as surgery, chemotherapy, and radiotherapy, challenges related to late-stage diagnosis, treatment resistance, and disease recurrence persist. The emergence of microRNAs (miRNAs) as key regulators of gene expression has revolutionized cancer diagnostics and therapeutics. Exosomal miRNAs, in particular, have garnered attention due to their stability, detectability in bodily fluids, and pivotal roles in tumor progression, metastasis, and immune modulation. This review provides a comprehensive overview of the role of exosomal miRNAs in the theranostic landscape of CC. We explore their involvement in disease pathogenesis, highlighting their potential as minimally invasive diagnostic biomarkers for early detection and disease monitoring. Furthermore, we examine their utility in therapeutic strategies, including miRNA-mediated drug delivery systems and miRNA-targeted interventions to overcome chemoresistance. Integrating exosomal miRNA profiling with current diagnostic modalities could enhance screening sensitivity and specificity, while miRNA-based therapies offer novel avenues to improve treatment efficacy. This review discusses recent advancements in miRNA research, current challenges in clinical translation, and future perspectives on leveraging exosomal miRNAs for personalized CC care.
Keywords: Biomarkers; Cervical cancer; Exosomal miRNA; Personalized medicine; Targeted therapy; Theranostics; miRNA therapeutics.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict of interest to report. Ethical approval: Not applicable.
Similar articles
-
The role and diagnostic value of deregulated miRNAs in cervical cancer.Discov Oncol. 2025 May 25;16(1):922. doi: 10.1007/s12672-025-02744-4. Discov Oncol. 2025. PMID: 40413660 Free PMC article. Review.
-
Exosomal microRNAs: novel players in cervical cancer.Epigenomics. 2020 Sep;12(18):1651-1660. doi: 10.2217/epi-2020-0026. Epub 2020 Sep 22. Epigenomics. 2020. PMID: 32957811 Review.
-
Exosomal microRNAs: impact on cancer detection, treatment, and monitoring.Clin Transl Oncol. 2025 Jan;27(1):83-94. doi: 10.1007/s12094-024-03590-6. Epub 2024 Jul 6. Clin Transl Oncol. 2025. PMID: 38971914 Review.
-
Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities.J Cell Physiol. 2018 Sep;233(9):6370-6380. doi: 10.1002/jcp.26481. Epub 2018 Mar 25. J Cell Physiol. 2018. PMID: 29323722 Review.
-
Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors.Mol Cancer. 2019 Apr 2;18(1):76. doi: 10.1186/s12943-019-0999-x. Mol Cancer. 2019. PMID: 30940131 Free PMC article.
References
-
- Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):28–44. https://doi.org/10.1002/ijgo.13865 . - DOI
-
- Han L, Xu S, Zhou D, Chen R, Ding Y, Zhang M, et al. Unveiling the causal link between metabolic factors and ovarian cancer risk using Mendelian randomization analysis. Front Endocrinol. 2024;15:1401648. https://doi.org/10.3389/fendo.2024.1401648 . - DOI
-
- Wu N, Zhang X, Fang C, Zhu M, Wang Z, Jian L, et al. Progesterone enhances niraparib efficacy in ovarian cancer by promoting palmitoleic-acid-mediated ferroptosis. Research. 2024;7:0371. https://doi.org/10.34133/research.0371 . - DOI - PubMed - PMC
-
- Zhou J, Li H, Wu B, Zhu L, Huang Q, Guo Z, et al. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer. Sci Rep. 2024;14(1):1860. https://doi.org/10.1038/s41598-024-52413-9 . - DOI - PubMed - PMC
-
- Pang J, Ding N, Liu X, He X, Zhou W, Xie H, et al. Prognostic value of the baseline systemic immune-inflammation index in HER2-positive metastatic breast cancer: exploratory analysis of two prospective trials. Ann Surg Oncol. 2025;32(2):750–9. https://doi.org/10.1245/s10434-024-16454-8 . - DOI - PubMed